{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:14:26Z","timestamp":1788509666080,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"US FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104337","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:10:21Z","timestamp":1779289821000},"page":"104337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Simulation of nitrosamine drug substance-related impurities from secondary amine-related impurities in approved human drug products"],"prefix":"10.1016","volume":"115","author":[{"given":"Xiang","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-717X","authenticated-orcid":false,"given":"Jingyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ee-Sunn","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-9750","authenticated-orcid":false,"given":"Tyler","family":"Peryea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3057-0174","authenticated-orcid":false,"given":"Tim","family":"Marzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3649-0449","authenticated-orcid":false,"given":"Diaa","family":"Shakleya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-7904","authenticated-orcid":false,"given":"David","family":"Keire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5981-6983","authenticated-orcid":false,"given":"Andre","family":"Raw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.xphs.2026.104337_bib0001","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.xphs.2023.03.022","article-title":"N-nitrosamine mitigation with nitrite scavengers in oral pharmaceutical drug products","volume":"112","author":"Bayne","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104337_bib0002","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: control of nitrosamine impurities in human drugs. 2024."},{"key":"10.1016\/j.xphs.2026.104337_bib0003","unstructured":"U.S. Food and Drug Administration. Guidance for industry: recommended acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs). 2023."},{"key":"10.1016\/j.xphs.2026.104337_bib0004","unstructured":"The European Medicines Agency. Nitrosamine impurities in human medicinal products. 2020."},{"key":"10.1016\/j.xphs.2026.104337_bib0005","unstructured":"The European Medicines Agency. Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products. 2025."},{"key":"10.1016\/j.xphs.2026.104337_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105640","article-title":"Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: development and application of the Carcinogenic Potency Categorization Approach (CPCA)","volume":"150","author":"Kruhlak","year":"2024","journal-title":"Regul Toxicol Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2026.104337_bib0007","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","article-title":"The landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Schlingemann","year":"2023","journal-title":"J Pharm Sci-Us"},{"issue":"12","key":"10.1016\/j.xphs.2026.104337_bib0008","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.xphs.2023.10.001","article-title":"Revisiting the landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Burns","year":"2023","journal-title":"J Pharm Sci-Us"},{"issue":"D1","key":"10.1016\/j.xphs.2026.104337_bib0009","doi-asserted-by":"crossref","first-page":"D1179","DOI":"10.1093\/nar\/gkaa962","article-title":"Global substance registration system: consistent scientific descriptions for substances related to health","volume":"49","author":"Peryea","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xphs.2026.104337_bib0010","unstructured":"U.S. Food and Drug Administration. FDA's global substance registration system. Available at: https:\/\/www.fda.gov\/industry\/fda-data-standards-advisory-board\/fdas-global-substance-registration-system#:~:text=FDA's%20GSRS%20generates%20Unique%20Ingredient,product%20marketing%20and%20postmarket%20surveillance. Accessed 4\/28\/2026."},{"key":"10.1016\/j.xphs.2026.104337_bib0011","unstructured":"U.S. Food and Drug Administration. FeaturizeNitrosamines. Available at: https:\/\/github.com\/FDA\/featurize-nitrosamines. Accessed 4\/28\/2026."},{"key":"10.1016\/j.xphs.2026.104337_bib0012","unstructured":"U.S. Food and Drug Administration. CDER nitrosamine impurity acceptable intake limits. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cder-nitrosamine-impurity-acceptable-intake-limits. Accessed 4\/28\/2026."},{"key":"10.1016\/j.xphs.2026.104337_bib0013","series-title":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q3A(R2): IMPURITIES IN NEW DRUG SUBSTANCES","year":"2006"},{"key":"10.1016\/j.xphs.2026.104337_bib0014","series-title":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q3B(R2): IMPURITIES IN NEW DRUG PRODUCTS","year":"2006"},{"issue":"11","key":"10.1016\/j.xphs.2026.104337_bib0015","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1021\/acs.oprd.5b00091","article-title":"Strategies to address mutagenic impurities derived from degradation in drug substances and drug products","volume":"19","author":"Kleinman","year":"2015","journal-title":"Org Process Res Dev"},{"issue":"10","key":"10.1016\/j.xphs.2026.104337_bib0016","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org Process Res Dev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:36:28Z","timestamp":1788507388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926001863"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104337","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simulation of nitrosamine drug substance-related impurities from secondary amine-related impurities in approved human drug products","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104337"}}